News

Cardionovum GmbH announced that it has initiated a 150-patient clinical study of its novel paclitaxel-releasing, high-pressure shunt balloon dilatation catheter, Aperto.

Balloon catheter, interventional radiology, FDA clearance, kidney disease

Covidien announced that it received U.S. Food and Drug Administration 510(k) clearance for its Fortrex over-the-wire (OTW) percutaneous transluminal angioplasty (PTA) balloon catheter.

TriReme, PTA Chocolate Balloon, valvuloplasty, heart valve repair

Catalist-listed QT Vascular Ltd. has acquired a novel technology platform called Java, and all associated intellectual property, which was developed independently in Israel.

Shockwave, lithoplasty, lithotripsy

Shockwave Medical announced positive clinical results from Disrupt PAD, a single-arm multicenter study evaluating the safety and utility of Lithoplasty balloon catheters for the treatment of...

Shockwave Medical announced that the company will present clinical results from DISRUPT PAD, a single-arm multicenter study evaluating the safety and utility of Lithoplasty balloon catheters for...

FDA Clears Lutonix 035 Drug Coated Balloon C.R. Bard Inc.

C. R. Bard Inc. announced the U.S. Food and Drug Administration (FDA) approval of the Lutonix 035 drug-coated balloon (DCB) catheter for percutaneous transluminal angioplasty (PTA) after pre-...

A new clinical trial comparing the use of everolimus-eluting stents (EES) and drug-eluting balloons (DEB) in treating in-stent restenosis (ISR) from drug-eluting stents found that EES provided...

September 11, 2014 — Medtronic announced the U.S. Food and Drug Administration (FDA) 510(k) clearance and launch of the NC Euphora noncompliant balloon dilatation catheter. The new device will be...

Teleflex Inc.’s subsidiary Hotspur Technologies Inc. received U.S. Food and Drug Administration (FDA) 510(k) clearance to market the Arrow GPSCath Balloon Dilatation Catheters designed for use...

Boston Scientific Corp. CE mark Ranger Ranger Paclitaxel-coated PTA Balloon Cath

Boston Scientific received CE mark for the Ranger Paclitaxel-coated PTA Balloon Catheter. The technology is now in full European market launch. 

agent, boston scientific, balloon catheter

The Agent Drug-Coated Balloon (DCB) provides physicians with an additional alternative to treat both in-stent restenosis (ISR) and de novo small vessel coronary disease.

July 11, 2014 — Cordis Corp. announced the launch of its Saber PTA (percutaneous transluminal angioplasty) dilatation catheter for the treatment of patients with peripheral arterial disease (PAD...

FDA Recommendation Lutonix Drug Coated Balloon Catheter

C. R. Bard Inc. announced that the U.S. Food and Drug Administration’s (FDA) Circulatory System Devices Advisory Panel provided a unanimous favorable recommendation to FDA for use of the Lutonix...

Medtronic Inc. announced CE mark and launch of the NC Euphora noncompliant balloon dilatation catheter. 

OrbusNeich announced the launch of the Sapphire II NC coronary dilatation catheter, a non-compliant balloon catheter engineered to cross tight lesions, outside the United States.

Interim results from The Chocolate Bar Registry conducted in the United States demonstrate that use of the Chocolate PTA balloon achieved high rates of treatment success and limb preservation in...

March 3, 2014 — Biotronik announced the release of its Passeo-18 Lux drug-releasing balloon (DRB) in all countries...

Cordis Trieme Chocolate PTA Balloon Catheter Peripheral Artery Disease PAD

Cordis Corp. announced an agreement with TriReme Medical Inc. that grants the company exclusive distribution rights for the Chocolate PTA Balloon Catheter. 

balloon catheters peripheral artery disease intact vascular tack-it

Intact Vascular Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, announced the start of enrollment in the Tack Optimized ...

balloon catheters cath lab drug-eluting clinical trials angioscore angiosculpt

AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease...